Hologic, Inc. (NASDAQ:HOLX) Stock Position Cut by Moody National Bank Trust Division

Moody National Bank Trust Division lessened its stake in Hologic, Inc. (NASDAQ:HOLXGet Rating) by 63.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,236 shares of the medical equipment provider’s stock after selling 17,663 shares during the period. Moody National Bank Trust Division’s holdings in Hologic were worth $709,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HOLX. American Trust boosted its position in shares of Hologic by 31.9% during the 1st quarter. American Trust now owns 5,171 shares of the medical equipment provider’s stock valued at $397,000 after purchasing an additional 1,252 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Hologic by 10.0% during the 1st quarter. Bank of America Corp DE now owns 1,621,825 shares of the medical equipment provider’s stock valued at $124,587,000 after purchasing an additional 147,122 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Hologic by 23.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,154 shares of the medical equipment provider’s stock valued at $2,778,000 after purchasing an additional 6,948 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Hologic during the 1st quarter valued at about $264,000. Finally, Toroso Investments LLC boosted its position in shares of Hologic by 7.4% during the 1st quarter. Toroso Investments LLC now owns 32,385 shares of the medical equipment provider’s stock valued at $2,488,000 after purchasing an additional 2,245 shares in the last quarter. Institutional investors own 85.70% of the company’s stock.

Hologic Price Performance

NASDAQ HOLX opened at $66.82 on Friday. The company has a 50 day simple moving average of $70.09 and a 200-day simple moving average of $72.50. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32. The firm has a market capitalization of $16.68 billion, a price-to-earnings ratio of 11.27, a price-to-earnings-growth ratio of 0.77 and a beta of 1.05. Hologic, Inc. has a 52-week low of $66.36 and a 52-week high of $80.49.

Hologic (NASDAQ:HOLXGet Rating) last posted its quarterly earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.26. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $896.71 million. Hologic had a net margin of 28.93% and a return on equity of 37.48%. The firm’s revenue was down 14.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.33 earnings per share. Equities research analysts predict that Hologic, Inc. will post 5.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HOLX shares. Morgan Stanley reduced their price objective on shares of Hologic from $72.00 to $70.00 and set an “equal weight” rating for the company in a research report on Thursday, July 28th. BTIG Research lowered shares of Hologic from a “buy” rating to a “neutral” rating in a research report on Monday, July 18th. Bank of America lowered shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $81.00 to $75.00 in a research note on Wednesday, July 20th. Finally, UBS Group initiated coverage on shares of Hologic in a research note on Wednesday, July 20th. They set a “neutral” rating and a $73.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $76.71.

Hologic Profile

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

See Also

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXGet Rating).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.